Client Story

EUSA Pharma

London-based pharmaceutical company EUSA Pharma markets new drugs to combat serious diseases.

 

We were informed by the equity firm Essex Woodlands, which had invested in EUSA Pharma, and by the latter company itself that it was on the look-out for innovative drugs as part of its growth strategy.

Strategy and Growth
Buy-Side Advisory
Healthcare and Life Sciences
Reading Time 3 minutes
Key Results
Purchase of global marketing rights to dinutuximab beta
by EUSA Pharma, quickly managed to obtain European approval.
Development of dinutuximab beta
for the treatment of neuroblastoma, the second most common solid tumor in children, by the Austrian biotech company Apeiron.
Approval of the drug
in the pipeline in the USA (as of September 2017).

The challenge

  • We were informed by the equity firm Essex Woodlands, which had invested in EUSA Pharma, and by the latter company itself that it was on the look-out for innovative drugs as part of its growth strategy.
  • EUSA Pharma was willing to acquire the rights to drugs for which approval had yet to be granted. Seizing the initiative, our pharmaceutical team went in search of a suitable drug.
Dark blue Background with multiple viruses in the front.

The solution

Thanks to its network of medics and pharmaceutical experts, the team was able to identify Apeiron´s immunotherapy for the treatment of brain tumors as a suitable target for purchase. Apeiron itself lacked the resources for marketing.

The team of consultants arranged a meeting and EUSA Pharma lost no time in taking action: European approval was applied for shortly after the completion of due diligence and conclusion of the purchase contract, and granted soon afterwards. 

The deal would not have come about without the initiative, wealth of knowledge and network of them.
Lee Morley
CEO of EUSA Pharma 

Passion for resultsWhat our 
client says

Ready for tomorrow?Get in touch and see how our team can help you.

What's new?You might also be interested in...

Deal Announcement
October 2026
Fortlane Partners advised SPGPrints Group on the sale of its Austrian subsidiary, SPGPrints Austria, to Heliograph Holding
Fortlane Partners advised SPGPrints Group on the sale of its Austrian subsidiary, SPGPrints Austria, to Heliograph Holding (“Heliograph”). The transaction marks a strategic step for both parties, bringing together complementary expertise in pre-printing solutions and technologies.
Videocast
Transformentors
October 2026
#08 Hans Jürgen Bort: Ehem. HR Director Europe bei Modine
In this episode of TRANSFORMENTORS®, Dr Gunnar Binnewies of Fortlane Partners and Hans Jürgen Bort, a long-standing HR manager and former HR Director Europe at Modine, discuss a topic that is often overlooked in many restructuring processes – yet is crucial to a company’s long-term success: Why sustainable transformation goes far beyond staff cuts and cost reductions. When markets come under pressure, orders dry up and companies are forced to cut costs, management teams face a crucial question: How can the organisation be streamlined without jeopardising its future viability? What skills will be needed tomorrow? And how can a company become more efficient with fewer resources? This episode demonstrates why successful restructuring does not end with job cuts, but begins with a clear vision for the future of the business model, processes, leadership and skills. This episode demonstrates why successful restructuring does not end with job cuts, but begins with a clear vision for the future of the business model, processes, leadership and skills. The focus is on shared practical experiences from the automotive and supplier industries, strategic competence management, AI-supported skills analyses, process optimisation and the role of HR as a driver of business performance. It also covers the correct approach to works councils, the responsibilities of managers and surprising parallels between military leadership and business transformation. Open, nuanced and offering concrete insights drawn from over 30 years of leadership experience. An essential discussion for managing directors, HR managers, consultants and executives who view restructuring not merely as a cost-cutting measure, but as an opportunity to position companies for a sustainable future.
Deal Announcement
October 2026
Fortlane Partners advised the shareholders of L4A S.r.l. on the sale of a majority stake to an affiliate of H.I.G. Capital
Fortlane Partners advised the shareholders of L4A S.r.l. on the sale of a majority stake to an affiliate of H.I.G. Capital, a leading global alternative investment firm. L4A is a specialist provider of turnkey maintenance, renewal and upgrade services for airport airside, water and district heating infrastructure, serving leading Italian operators and utilities.